Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Total Non-Current Liabilities (2021 - 2025)

Senti Biosciences has reported Total Non-Current Liabilities over the past 5 years, most recently at $37.5 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 10.71% year-over-year to $37.5 million; the TTM value through Dec 2025 reached $37.5 million, down 10.71%, while the annual FY2025 figure was $37.5 million, 10.71% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $37.5 million at Senti Biosciences, up from $37.0 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $53.3 million in Q4 2022 and troughed at $36.3 million in Q2 2025.
  • A 5-year average of $43.6 million and a median of $43.4 million in 2023 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 46.73% in 2022 and later fell 20.04% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $36.3 million in 2021, then surged by 46.73% to $53.3 million in 2022, then decreased by 1.37% to $52.6 million in 2023, then fell by 20.04% to $42.0 million in 2024, then decreased by 10.71% to $37.5 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for SNTI at $37.5 million in Q4 2025, $37.0 million in Q3 2025, and $36.3 million in Q2 2025.